Product description

Letrozole is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery.

Letrozole API has got Chinese local GMP certificate and CEP certificate in Europe. It also has been approved by US-FDA and Japanese PMDA.
Currently, the sales of Letrozole FDF and API have covered over 10 countries in Europe, America and Asia.
Read more


Categories APIs
Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Supplied from China

More products from Jiangsu Hengrui Medicine Co., Ltd.

View all our products (78)

Products from other suppliers


Contact information




View all contact information